Roland Greinwald

Roland Greinwald. Head of R&D at Dr. Falk Pharma GmbH. He leads the global collaboration for Dr. Falk with Prometheus to develop and commercialize PR600 (anti-CD30 Ligand antibody), Prometheus’ cell signaling program that targets a receptor of the tumor-necrosis factor superfamily for the treatment of IBD. Prior to Dr. Falk Pharma, Mr. Greinwald was previously a researcher at the University of Wuerzburg in the department of pharmaceutical biology. Mr. Greinwald has authored more than 180 scientific publications and has numerous patents supporting many inflammatory therapeutic drug candidates and formulations.

Brian G. Feagan, M.D.

Brian G. Feagan, M.D. Gastroenterologist, epidemiologist and Senior Scientific Director at Alimentiv. He is the recipient of the 2013 Senior Achievement Award from the Crohn’s & Colitis Foundation of America (CCFA) and Dean’s Award of Excellence in 2013 from the University of Western Ontario. He has authored over 400 articles.

Timothy K. Andrews

Timothy K. Andrews has served as our General Counsel and Secretary since November 2020. From 2016 through 2019 he served as General Counsel and Secretary for Sienna Biopharmaceuticals, Inc., a publicly traded, clinical-stage biotech company, where he was instrumental in acquiring the company’s core assets, planning and executing its IPO, and building the legal function and corporate governance systems. Mr. Andrews served as Senior Corporate Counsel and Assistant Secretary at Allergan, Inc. from 2011 through 2015, when the company was acquired by Actavis plc. At Allergan, Inc., he had legal responsibility for U.S. and international business development transactions, including acquisitions, licensing and partnerships, as well as corporate governance and securities law compliance. From 2006 to 2011, Mr. Andrews was a corporate attorney at Latham & Watkins LLP, where his practice focused on public company representation, mergers and acquisitions and corporate finance, serving clients in the life sciences sector, including Allergan. He was previously a Business Analyst at Deloitte Consulting. Mr. Andrews received a B.A. in Political Economy from the University of California, Berkeley and a J.D. from Loyola Law School, Los Angeles.